UBM.MI Stock - Ulisse Biomed S.p.A.
Unlock GoAI Insights for UBM.MI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $407,786 | $66,208 | $138,437 | $280,440 | $429,000 |
| Gross Profit | $208,540 | $-1,549,058 | $-1,544,388 | $-657,750 | $200,000 |
| Gross Margin | 51.1% | -2339.7% | -1115.6% | -234.5% | 46.6% |
| Operating Income | $-1,449,853 | $-3,459,090 | $-1,700,470 | $-738,350 | $120,000 |
| Net Income | $-1,462,928 | $-4,796,847 | $-1,307,745 | $-603,599 | $222,000 |
| Net Margin | -358.7% | -7245.1% | -944.6% | -215.2% | 51.7% |
| EPS | $-0.06 | $-0.22 | $-0.16 | $-0.07 | $0.03 |
Ulisse Biomed S.p.A., a healthcare biotech company, provides diagnostic platforms and products. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It also provides various tests and reagents for sexually transmitted diseases and HPV for oropharyngeal cancer. In addition, the company's platforms also comprise NanoHybrid, a DNA/PNA based multi-modal biomolecule platform to detect specific antibodies and protein analytes directly from serum or whole blood; and Aptavir platform to develop and produce synthetic nucleic acid molecules to limit the infectivity of pathogens. Ulisse Biomed S.p.A. was founded in 2015 and is based in Udine, Italy.
Visit WebsiteEarnings History & Surprises
UBM.MIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 16, 2025 | — | — | — | — |
Q1 2025 | Mar 31, 2025 | — | $0.07 | — | — |
Q4 2024 | Oct 1, 2024 | — | $-0.14 | — | — |
Q2 2024 | Jun 24, 2024 | — | $-0.18 | — | — |
Q3 2023 | Sep 29, 2023 | — | $-0.11 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.10 | — | — |
Q4 2022 | Oct 1, 2022 | — | $-0.07 | — | — |
Q2 2022 | Apr 13, 2022 | — | $-0.06 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 31, 2020 | — | $0.04 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.01 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.07 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.07 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.13 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.13 | — | — |
Latest News
Frequently Asked Questions about UBM.MI
What is UBM.MI's current stock price?
What is the analyst price target for UBM.MI?
What sector is Ulisse Biomed S.p.A. in?
What is UBM.MI's market cap?
Does UBM.MI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to UBM.MI for comparison